Search
Now showing items 1-10 of 13
Gonadotropin-releasing hormone antagonist plus testosterone: a potential male contraceptive
(Endocrine Society, 1991-09)
No effective hormonal contraceptive has yet been devised for men. Through
their suppressive effect on gonadotropin secretion, GnRH antagonists
inhibit both testosterone (T) production and spermatogenesis in animals.
Long term administration of an antagonist alone would result in androgen
deficiency; ...
Testosterone-induced suppression of lipoprotein(a) in normal men; relation to basal lipoprotein(a) level
(Elsevier, 1996-04-26)
The concentration of lipoprotein(a) [Lp(a)] in human plasma is largely
genetically determined and is inversely correlated to the size of
apolipoprotein(a) [apo(a)]. Additionally, Lp(a) values are relatively
stable within individuals and are only marginally susceptible to
therapeutic treatment. The ...
Single-dose administration of the gonadotropin-releasing hormone antagonist, Nal-Lys (antide) to healthy men
(Elsevier, 1993-10)
OBJECTIVE: To evaluate the ability the Nal-Lys GnRH antagonist ([N-Ac-Nal
(2)1, 4ClDPhe2, D3Pal3, Lys (Nic)5, D-Lys(Nic)6, Lys (iPr)8, D-Ala10] to
suppress gonadotropins and T in humans and to assess its duration of
action and its local effects. DESIGN: Placebo-controlled clinical study.
SETTING: ...
The direct pituitary effect of testosterone to inhibit gonadotropin secretion in men is partially mediated by aromatization to estradiol
(American Society of Andrology, 1994-01)
In men, administration of exogenous testosterone (T) exerts direct
negative feedback effects at the pituitary as well as at the hypothalamic
level. This study was undertaken to determine whether T itself causes the
inhibitory effects on the pituitary, or whether conversion to estradiol
(E2) or ...
Metabolic and behavioral effects of high-dose, exogenous testosterone in healthy men
(Endocrine Society, 1994-08)
In addition to their use as replacement therapy for hypogonadal males,
androgens, particularly testosterone (T), are being explored as potential
hormonal male contraceptive agents, alone or in combination with other
compounds. Androgens have regulatory effects on a variety of physiological
systems ...
Physiological levels of estradiol stimulate plasma high density lipoprotein2 cholesterol levels in normal men
(Endocrine Society, 1994-04)
Premenopausal women have a lower risk of coronary artery disease than men
or postmenopausal women; estrogens are thought to contribute to this lower
risk. Administration of exogenous estrogen to post-menopausal women
increases plasma high density lipoprotein (HDL) cholesterol and may reduce
mortality ...
Effects of endogenous testosterone and estradiol on sexual behavior in normal young men
(Endocrine Society, 1994-03)
The importance of androgens in establishing and maintaining sexual
function in males of most species is well recognized. Estrogens also
stimulate male sexual function in some species. In men, most studies of
androgen effects on behavior have used hypogonadal men as an experimental
model; much less ...
Comparison of a gonadotropin releasing-hormone antagonist plus testosterone (T) versus T alone as potential male contraceptive regimens
(Endocrine Society, 1993-08)
Efforts to develop a hormonal contraceptive regimen for men have focused
on administration of testosterone (T), alone or together with other
agents. Previous regimens have successfully induced azoospermia in only
50-70% of subjects, however. GnRH antagonists, alone or in combination
with T, have ...
Sperm counts and reproductive hormones in male marathoners and lean controls
(Elsevier, 1990-04)
In women, chronic and intense endurance exercise is frequently associated
with menstrual cycle alterations. In men, the effects of similar amounts
of exercise are less well-studied. We tested the hypothesis that endurance
exercise in men is also associated with alterations in reproductive
function. ...
Dose effects of the gonadotropin-releasing hormone antagonist, Nal-Glu, combined with testosterone enanthate on gonadotropin levels in normal men
(Elsevier, 1995-07)
OBJECTIVE: To test the hypothesis that over a 4-week treatment period,
Nal-Glu GnRH antagonist ([AcD2Nal1, D4ClPhe2, D3Pal3, Arg5, DGlu6 [AA],
DAla10] GnRH) at a dose of 200 micrograms/kg per day SC would suppress
levels of immunologically active and biologically active LH and FSH more
completely ...